文献速递先天性心脏病外科瓣膜外科

儿童心脏手术后阿司匹林反应性的前瞻性队列研究

Platelet responsiveness to aspirin in pediatric patients undergoing cardiac surgery: A prospective cohort study.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-09-18

本研究在2022至2024年纳入133例0至18岁心脏术后需阿司匹林预防血栓的患儿,用光透射聚集法(LTA)检测标准剂量5 mg/kg或150 mg(取较小者)的阿司匹林反应性。18%患儿对标准剂量无反应,多数对增量至10 mg/kg有反应,仅5%为真正阿司匹林抵抗;血栓弹力图血小板图(TEG-PM)与LTA无相关性。

要点

  • 儿童心脏术后约18%对标准5 mg/kg阿司匹林无反应,仅5%为真正抵抗。
  • 多数无反应者增量至10 mg/kg后反应性恢复。
  • TEG-PM与金标准LTA检测阿司匹林反应性无相关性。

核心结论

  • 近20%儿童心脏手术患者对标准5 mg/kg阿司匹林剂量无反应,多数呈剂量依赖反应,仅5%为真正阿司匹林抵抗。

研究设计与样本

  • 前瞻性队列研究(注册号ACTRN12618001879257),2022至2024年单中心纳入133例0至18岁心脏术后需阿司匹林预防的患儿。

主要发现

  • 24例(18%)对标准剂量无反应,23例(17%)增量,20例(15%)复测,13例(10%)对10 mg/kg有反应,7例(5%)为阿司匹林抵抗。
  • LTA与TEG-PM检测阿司匹林反应性无相关性(P = .167)。
  • 未发现阿司匹林无反应的可识别危险因素。

关键数值与推荐

  • LTA定义阿司匹林无反应:花生四烯酸诱导血小板聚集≥20%或二磷酸腺苷诱导聚集≥70%。
  • TEG-PM定义阿司匹林无反应:血小板聚集≥50%。
  • 标准阿司匹林剂量为5 mg/kg或150 mg(取较小者),至少3天后检测。

临床怎么用

  • 对血栓风险高的儿童心脏术后患者可考虑检测阿司匹林反应性,无反应者增量至10 mg/kg并复测。
  • TEG-PM不能替代LTA用于评估阿司匹林反应性。

局限性

  • 需进一步证据关联临床结局以明确检测阿司匹林反应性的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspirin at 3 to 5 mg/kg is the cornerstone of thromboprophylaxis in pediatric cardiac surgery. The reported prevalence of aspirin unresponsiveness is 1% to 35% in adults and 10% to 15% in children. The present study aimed to (1) describe the prevalence of aspirin responsiveness in the pediatric cardiac surgical population using light transmission aggregometry (LTA), the gold standard; (2) evaluate the dose-dependent response to aspirin; (3) compare LTA with point-of-care thromboelastography with platelet mapping (TEG-PM); and (4) describe adverse events and report a risk factor analysis. METHODS: This prospective cohort study (Clinical Trials Registry ACTRN12618001879257) was conducted from 2022 to 2024 in a quaternary children's hospital and included patients age 0 to 18 years who required aspirin prophylaxis after cardiac surgery. Patients who were allergic to aspirin or received other anticoagulants, such as warfarin, were excluded. Aspirin responsiveness was tested after at least 3 days of a standard aspirin dose of 5 mg/kg or 150 mg (whichever was less). LTA showing ≥20% platelet aggregation stimulated by arachidonic acid or ≥70% platelet aggregation to adenosine diphosphate denoted aspirin unresponsiveness. To evaluate TEG-PM compared to the gold standard (LTA), TEG-PM showing ≥50% platelet aggregation denoted aspirin unresponsiveness. The dose was increased to 10 mg/kg in these patients, and aspirin responsiveness was reevaluated. Those patients still not responding were labeled "aspirin-resistant." RESULTS: The 133 eligible patients included 77 males (58%), 49 with a single ventricle (37%), and 119 who underwent surgery using cardiopulmonary bypass (89%). The most common indications for aspirin were shunts/Fontan in single ventricle patients (n = 44; 33%) and valve repair/replacement (n = 25; 19%). The median patient age was 1.9 years (interquartile range [IQR], 0.13-12 years), and the median weight was 15.1 kg (IQR, 4.2-44.1 kg). Twenty-four patients (18%) did not respond to the standard aspirin dose, and the dose was increased in 23 patients (17%). Twenty patients (15%) were tested a second time; 13 (10%) responded to the increased aspirin dose (10 mg/kg). Seven patients (5%) were aspirin-resistant. There was no correlation between the results of aspirin responsiveness tested using LTA and TEG-PM (P = .167). There were no identifiable risk factors for aspirin unresponsiveness. CONCLUSIONS: Almost 20% of pediatric cardiac surgical patients do not respond to a standard 5 mg/kg aspirin dose. Most non-responders have a dose-dependent response to aspirin. Only 5% of patients are genuinely aspirin-resistant (as defined by LTA). TEG-PM does not correlate with the gold standard LTA test to determine aspirin responsiveness. Testing for aspirin responsiveness should be considered in patients undergoing pediatric cardiac surgery who are at risk of clinically significant thrombosis; however, further evidence with correlation to clinical outcomes is needed to define the utility of testing for aspirin responsiveness.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Marathe SP, Van Dyk S, Campbell S, et al. Platelet responsiveness to aspirin in pediatric patients undergoing cardiac surgery: A prospective cohort study. J Thorac Cardiovasc Surg. 2025. PMID: 40975432. doi:10.1016/j.jtcvs.2025.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。